Siavash Beikoghli Kalkhoran, Janos Kriston-Vizi, Sauri Hernandez-Resendiz, Gustavo E Crespo-Avilan, Ayeshah A Rosdah, Jarmon G Lees, Joana Rodrigues Simoes Da Costa, Naomi X Y Ling, Jessica K Holien, Parisa Samangouei, Kroekkiat Chinda, En Ping Yap, Jaime A Riquelme, Robin Ketteler, Derek M Yellon, Shiang Y Lim, Derek J Hausenloy
AIMS: Genetic and pharmacological inhibition of mitochondrial fission induced by acute myocardial ischaemia/reperfusion injury (IRI) has been shown to reduce myocardial infarct size. The clinically used anti-hypertensive and heart failure medication, hydralazine, is known to have anti-oxidant and anti-apoptotic effects. Here, we investigated whether hydralazine confers acute cardioprotection by inhibiting Drp1-mediated mitochondrial fission. METHODS AND RESULTS: Pre-treatment with hydralazine was shown to inhibit both mitochondrial fission and mitochondrial membrane depolarisation induced by oxidative stress in HeLa cells...
January 7, 2022: Cardiovascular Research